Logo of National Eczema Association mobile menu icon
Icon link to National Eczema's Instagram feed. Icon link to National Eczema's YouTube channel. Icon link to National Eczema's Facebook page. Icon link to National Eczema's Twitter feed. Eczema-wise logo link to National Eczema's inspire.com page. Search Icon to search the site

Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.
 

Search Results for “dupilumab”


Another Step Closer

…and improved patient quality of life in adults with AD when dupilumab was used alone (without a topical corticosteroid). Dupilumab is an injectable, biologic medication, which is a class of…

Read More


Understanding Biologic Drugs

Biologic drugs have been making headlines as potentially promising new therapies for treating atopic dermatitis (AD). Several have shown positive results in clinical trials and one, dupilumab, is being reviewed…

Read More


American Academy of Dermatology 2017 Annual Meeting Highlights

…their treatment with dupilumab alone, dupilumab and a steroid in combination or a steroid alone. Dupilumab targets IL-4 and IL-13 to regulate the immune system response in atopic dermatitis. The…

Read More


NEA Celebrates Another Win for Access to New Atopic Dermatitis Therapy Dupixent

dupilumab offers “high value” for adults with severe AD and “intermediate value” for those with moderate disease. The report noted there was enough evidence to consider dupilumab as “superior” in…

Read More


Top Advances in Eczema Research in 2016

…Seattle, Washington and co-chair of NEA’s Scientific Advisory Committee to identify some of the 2016 research highlights. Here are his top five: Results from the phase III trial of dupilumab

Read More


Take charge of your eczema!

…By stopping the immune system from overreacting, dupilumab lowers inflammation and other symptoms of AD. “Dupilumab has shown strong efficacy and safety for treatment of moderate to severe AD in…

Read More


A Second Biologic Drug for Atopic Dermatitis Makes Its Way to Market

Following on the heels of Dupixent (dupilumab)—the first-ever biologic drug for atopic dermatitis (the most common type of eczema), approved by the U.S. Food and Drug Administration (FDA) on March…

Read More


Never Lose Hope

…burned all the time. But after dupilumab, I felt relief.” Immunoglobulin E (IgE) is an antibody that is produced by the body’s immune system in response to a perceived threat,…

Read More


Eczema Awareness Month Kicks-Off with Groundbreaking News

…come to market as soon as spring 2017. Patients who have participated in clinical trials of dupilumab shared their stories with The New York Times in an article published today:…

Read More


Biologics

…lower or less severe inflammation and therefore fewer symptoms of atopic dermatitis. Dupixent (dupilumab) Dupixent (dupilumab) is the first biologic medication approved by the U.S. Food and Drug Administration (FDA)…

Read More